CCL2 and obesity disorder: JNK inhibition reduces the release of IR-related pro-inflammatory cytokines such as TNFα and MCP-1 and represents an attractive opportunity to improve metabolic dysfunction in obesity by preventing excessive adiposity, insulin resistance and inflammation [45].